vs
Side-by-side financial comparison of AMERISAFE INC (AMSF) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $80.1M, roughly 1.6× AMERISAFE INC). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 10.3%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 2.8%).
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
AMSF vs TVTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $80.1M | $129.7M |
| Net Profit | $8.1M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | — | -25.0% |
| Net Margin | 10.2% | — |
| Revenue YoY | 10.3% | 73.4% |
| Net Profit YoY | -9.0% | — |
| EPS (diluted) | $0.43 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $80.1M | — | ||
| Q4 25 | $81.6M | $129.7M | ||
| Q3 25 | $82.0M | $164.9M | ||
| Q2 25 | $81.1M | $114.4M | ||
| Q1 25 | $72.6M | $81.7M | ||
| Q4 24 | $74.0M | $74.8M | ||
| Q3 24 | $78.7M | $62.9M | ||
| Q2 24 | $75.8M | $54.1M |
| Q1 26 | $8.1M | — | ||
| Q4 25 | $10.4M | — | ||
| Q3 25 | $13.8M | $25.7M | ||
| Q2 25 | $14.0M | $-12.8M | ||
| Q1 25 | $8.9M | $-41.2M | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $14.3M | $-54.8M | ||
| Q2 24 | $11.0M | $-70.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | -25.0% | ||
| Q3 25 | 21.3% | 15.1% | ||
| Q2 25 | 21.5% | -11.1% | ||
| Q1 25 | 15.5% | -52.2% | ||
| Q4 24 | 22.7% | -81.2% | ||
| Q3 24 | 22.6% | -89.3% | ||
| Q2 24 | 18.1% | -125.1% |
| Q1 26 | 10.2% | — | ||
| Q4 25 | 12.8% | — | ||
| Q3 25 | 16.9% | 15.6% | ||
| Q2 25 | 17.2% | -11.1% | ||
| Q1 25 | 12.3% | -50.4% | ||
| Q4 24 | 17.8% | — | ||
| Q3 24 | 18.2% | -87.1% | ||
| Q2 24 | 14.5% | -130.1% |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.55 | $0.04 | ||
| Q3 25 | $0.72 | $0.28 | ||
| Q2 25 | $0.73 | $-0.14 | ||
| Q1 25 | $0.47 | $-0.47 | ||
| Q4 24 | $0.69 | $-0.71 | ||
| Q3 24 | $0.75 | $-0.70 | ||
| Q2 24 | $0.57 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.2M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $246.6M | $114.8M |
| Total Assets | — | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.2M | — | ||
| Q4 25 | $61.9M | $93.0M | ||
| Q3 25 | $54.7M | $110.9M | ||
| Q2 25 | $48.5M | $75.2M | ||
| Q1 25 | $44.8M | $61.9M | ||
| Q4 24 | $44.1M | $58.5M | ||
| Q3 24 | $63.7M | $36.4M | ||
| Q2 24 | $30.6M | $32.3M |
| Q1 26 | $246.6M | — | ||
| Q4 25 | $251.6M | $114.8M | ||
| Q3 25 | $274.8M | $73.6M | ||
| Q2 25 | $265.6M | $32.7M | ||
| Q1 25 | $260.8M | $32.8M | ||
| Q4 24 | $257.3M | $59.1M | ||
| Q3 24 | $314.4M | $-30.5M | ||
| Q2 24 | $301.0M | $15.1M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $605.2M | ||
| Q3 25 | $1.2B | $538.6M | ||
| Q2 25 | $1.2B | $555.3M | ||
| Q1 25 | $1.2B | $548.8M | ||
| Q4 24 | $1.2B | $594.1M | ||
| Q3 24 | $1.3B | $504.4M | ||
| Q2 24 | $1.2B | $551.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $11.1M | $60.7M | ||
| Q3 25 | $10.7M | $14.3M | ||
| Q2 25 | $-8.4M | $5.0M | ||
| Q1 25 | $-1.8M | $-42.2M | ||
| Q4 24 | $24.2M | $-35.7M | ||
| Q3 24 | $8.4M | $-42.5M | ||
| Q2 24 | $-2.6M | $-40.2M |
| Q1 26 | — | — | ||
| Q4 25 | $8.9M | — | ||
| Q3 25 | $9.8M | $14.2M | ||
| Q2 25 | $-9.5M | — | ||
| Q1 25 | $-1.8M | — | ||
| Q4 24 | $23.4M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $-2.6M | $-40.3M |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | — | ||
| Q3 25 | 11.9% | 8.6% | ||
| Q2 25 | -11.7% | — | ||
| Q1 25 | -2.5% | — | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | -3.5% | -74.5% |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.1% | 0.1% | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.1% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.06× | — | ||
| Q3 25 | 0.77× | 0.56× | ||
| Q2 25 | -0.61× | — | ||
| Q1 25 | -0.20× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 0.59× | — | ||
| Q2 24 | -0.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMSF
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
